Moosavyzadeh Abdolali, Ghaffari Farzaneh, Saberizafarghandi Mohammad Bagher, Talafi Noghani Majid, Hassanpour Hossein, Emadi Fatemeh, Alijaniha Fatemeh, Bahaeddin Zahra, Nasiri Leila, Jafari Hajati Razieh, Naseri Mohsen
Department of Persian Medicine, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran.
Caspian J Intern Med. 2024 Spring;15(2):318-327. doi: 10.22088/cjim.15.2.318.
Opioid dependence, is one of the world's most critical health problems. Deaddicta is a herbal product considered an effective treatment for opioid addiction. Deaddicta's efficacy in the maintenance treatment of patients with opioid use disorder has recently been demonstrated through a double-blind randomized controlled trial (RCT). This study aimed to evaluate the permanence of Deaddicta's efficacy six months after the end of the maintenance treatment for opioid dependence.
This study was performed following the previous RCT on the maintenance treatment of opioid addicts. Out of 41 participants who completed the study for three months in the previous research, 15 from the intervention group (Deaddicta capsules, 1500 mg/day) returned for follow-up. They all previously fulfilled the DSM-IV criteria for addiction, were aged 18 to 65, and had discontinued Deaddicta for six months. The outcome measures included addiction severity, depression and anxiety levels, and craving score. The scores of each parameter were compared in three phases: before intervention; after three months of intervention; and six months after the end of the study.
Depression, anxiety, and craving scores decreased six months after the end of the previous study. This decrease was significant in the craving score ( = 0.011). No significant increase was observed in the frequency of use. The regression analysis showed a negative relationship between craving and the progression of phases.
The Deaddicta product may have desirable and effective properties in decreasing temptation and, as a result, the maintenance treatment of opioid dependence.
阿片类药物依赖是世界上最严重的健康问题之一。Deaddicta是一种草药产品，被认为是治疗阿片类药物成瘾的有效方法。最近通过一项双盲随机对照试验（RCT）证明了Deaddicta在维持治疗阿片类药物使用障碍患者中的疗效。本研究旨在评估在阿片类药物依赖维持治疗结束六个月后Deaddicta疗效的持续性。
本研究是在之前关于阿片类药物成瘾者维持治疗的RCT基础上进行的。在之前研究中完成三个月研究的41名参与者中，干预组（Deaddicta胶囊，1500毫克/天）的15人返回进行随访。他们之前均符合DSM-IV成瘾标准，年龄在18至65岁之间，且已停用Deaddicta六个月。结局指标包括成瘾严重程度、抑郁和焦虑水平以及渴求评分。在三个阶段比较每个参数的得分：干预前；干预三个月后；研究结束后六个月。
在前一项研究结束六个月后，抑郁、焦虑和渴求评分下降。渴求评分的下降具有显著性（P = 0.011）。使用频率未观察到显著增加。回归分析显示渴求与阶段进展之间存在负相关关系。
Deaddicta产品在降低诱惑方面可能具有理想且有效的特性，因此可用于阿片类药物依赖的维持治疗。
